SCHEMBL4779554

SCHEMBL4779554

CCOC(=O)c1ccnc(C)c1C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 1/20 0.55
TSHR P16473 2/20 0.53
ALDH1A1 P00352 5/20 0.46
HSD17B10 Q99714 1/20 0.46
CA12 O43570 2/20 0.45
CA1 P00915 2/20 0.45
CA2 P00918 2/20 0.45
CA7 P43166 2/20 0.45
CA9 Q16790 2/20 0.45
CA14 Q9ULX7 2/20 0.45
CYP1A2 P05177 1/20 0.44
KDM4E B2RXH2 3/20 0.44
HTT P42858 1/20 0.43
RAB9A P51151 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
KMT2A Q03164 2/20 0.42
MAPT P10636 2/20 0.42
MEN1 O00255 1/20 0.42
LMNA P02545 1/20 0.42
MAPK1 P28482 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28974250 0.84 NUDT1 (0.54) NUDT1TSHRALDH1A1HSD17B10CA12
SCHEMBL12633740 0.83 NUDT1 (0.56) NUDT1TSHRALDH1A1HSD17B10CYP1A2
SCHEMBL14661485 0.83 NUDT1 (0.52) NUDT1TSHRALDH1A1HSD17B10CA12
SCHEMBL17295833 0.83 NUDT1 (0.52) NUDT1TSHRALDH1A1HSD17B10CA12
SCHEMBL231051 0.83 NUDT1 (0.52) NUDT1TSHRALDH1A1HSD17B10CA12
SCHEMBL13041779 0.81 KDM4E (0.47) TSHRALDH1A1HSD17B10KDM4ERAB9A
SCHEMBL23674700 0.81 NUDT1 (0.51) NUDT1TSHRALDH1A1HSD17B10CA12
SCHEMBL5489653 0.81 NUDT1 (0.51) NUDT1TSHRALDH1A1HSD17B10CA12
SCHEMBL109206 0.79 TSHR (0.63) TSHRALDH1A1HSD17B10CYP1A2HTT
SCHEMBL29571304 0.79 TSHR (0.63) TSHRALDH1A1HSD17B10CYP1A2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008016811-A2 AMINOPIPERIDINES AND REALTED COMPOUNDS NEUROGEN CORPORATION (US) 2008-02-07 WO disclosed
WO-2008016811-A2 AMINOPIPERIDINES AND REALTED COMPOUNDS NEUROGEN CORPORATION (US) 2008-02-07 WO disclosed
US-20050239791-A1 Substituted 1-heteroaryl-4-substituted piperazine and piperidine analogues NEUROGEN CORPORATION 2005-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239791-A1 Substituted 1-heteroaryl-4-substituted piperazine and piperidine analogues MCHR1, MCHR2, PRLHR NUDT1 3906/4885TSHR 159/4885ALDH1A1 802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.